Lopinavir-ritonavir-based antiretroviral therapy significantly accelerated suppression of the Epstein-Barr virus among infants with HIV, according to a study in Clinical Infectious Diseases.
The study cohort consisted of 64 infants with a median age of 3.6 months who were living in Nairobi and had not received ART prior to the study. Jennifer A. Slyker, PhD, and colleagues followed study participants for a median of 24 months. The mean CD4 count was low at baseline (20%, +SD 8.3). Antiretroviral therapy began at a median age of 4.1 months; 34 participants received lopinavir-ritonavir and 30 received nevirapine.Full Story »